Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, T-Cell, Peripheral

Explore clinical trials studying Lymphoma, T-Cell, Peripheral. Study availability and eligibility vary by location and protocol.

15 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, T-Cell, Peripheral trial results

Recruiting

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048

Conditions
Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Hemic and Lymphatic Diseases, +16 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California, Irvine Irvine, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Yale University New Haven, Connecticut, United States
View all 34 locations
View Trial Details
Completed

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

NCT01155817

Conditions
Bone Marrow Transplant Failure, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Stanford University School of Medicine Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • Fred Hutchinson Cancer Research Center Seattle, Washington, United States
View Trial Details
Completed

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

NCT00211185

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Birmingham Hematology and Oncology Birmingham, Alabama, United States
  • Hematology Oncology Associates Phoenix, Arizona, United States
  • Stanford Cancer Center Stanford, California, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
View all 49 locations
View Trial Details
Completed

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • City of Hope Duarte, California, United States
  • Chao Family Comprehensive Cancer Center University of California Irvine Orange, California, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Emory University School of Medicine Atlanta, Georgia, United States
View Trial Details

Related conditions